Evidence map›Paper›PMID 39661921›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2025

Multimodal Longitudinal Optical Imaging Reveals Optic Neuritis Preceding Retinal Pathology in Experimental Autoimmune Encephalomyelitis.

Raphael Raspe, Robert Günther, Ralf Uecker, Asylkhan Rakhymzhan, Friedemann Paul, Helena Radbruch, Raluca Aura Niesner, Anja Erika Hauser

Abstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Ocular manifestations in autism spectrum disorder.International journal of ophthalmology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Raphael RaspeFrom the Departments of Rheumatology and Clinical Immunology (R.R., A.E.H., R.U.) and Neuropathology (R.R., H.R.), Charité - Universitätsmedizin Berlin; Deutsches Rheuma-Forschungszentrum, a Leibniz Institute, Immune Dynamics (A.E.H., R.G.) and Biophysical Analytics (A.R., R.A.N.), Berlin; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin (F.P.), Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max-Delbrueck Center for Molecular Medicine (F.P.); and Dynamic and Functional in vivo Imaging, Freie Universität (R.A.N.) Berlin, Germany.
Robert GüntherFrom the Departments of Rheumatology and Clinical Immunology (R.R., A.E.H., R.U.) and Neuropathology (R.R., H.R.), Charité - Universitätsmedizin Berlin; Deutsches Rheuma-Forschungszentrum, a Leibniz Institute, Immune Dynamics (A.E.H., R.G.) and Biophysical Analytics (A.R., R.A.N.), Berlin; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin (F.P.), Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max-Delbrueck Center for Molecular Medicine (F.P.); and Dynamic and Functional in vivo Imaging, Freie Universität (R.A.N.) Berlin, Germany.
Ralf UeckerFrom the Departments of Rheumatology and Clinical Immunology (R.R., A.E.H., R.U.) and Neuropathology (R.R., H.R.), Charité - Universitätsmedizin Berlin; Deutsches Rheuma-Forschungszentrum, a Leibniz Institute, Immune Dynamics (A.E.H., R.G.) and Biophysical Analytics (A.R., R.A.N.), Berlin; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin (F.P.), Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max-Delbrueck Center for Molecular Medicine (F.P.); and Dynamic and Functional in vivo Imaging, Freie Universität (R.A.N.) Berlin, Germany.
Asylkhan RakhymzhanFrom the Departments of Rheumatology and Clinical Immunology (R.R., A.E.H., R.U.) and Neuropathology (R.R., H.R.), Charité - Universitätsmedizin Berlin; Deutsches Rheuma-Forschungszentrum, a Leibniz Institute, Immune Dynamics (A.E.H., R.G.) and Biophysical Analytics (A.R., R.A.N.), Berlin; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin (F.P.), Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max-Delbrueck Center for Molecular Medicine (F.P.); and Dynamic and Functional in vivo Imaging, Freie Universität (R.A.N.) Berlin, Germany.
Friedemann PaulFrom the Departments of Rheumatology and Clinical Immunology (R.R., A.E.H., R.U.) and Neuropathology (R.R., H.R.), Charité - Universitätsmedizin Berlin; Deutsches Rheuma-Forschungszentrum, a Leibniz Institute, Immune Dynamics (A.E.H., R.G.) and Biophysical Analytics (A.R., R.A.N.), Berlin; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin (F.P.), Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max-Delbrueck Center for Molecular Medicine (F.P.); and Dynamic and Functional in vivo Imaging, Freie Universität (R.A.N.) Berlin, Germany.ORCID 0000-0002-6378-0070
Helena RadbruchFrom the Departments of Rheumatology and Clinical Immunology (R.R., A.E.H., R.U.) and Neuropathology (R.R., H.R.), Charité - Universitätsmedizin Berlin; Deutsches Rheuma-Forschungszentrum, a Leibniz Institute, Immune Dynamics (A.E.H., R.G.) and Biophysical Analytics (A.R., R.A.N.), Berlin; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin (F.P.), Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max-Delbrueck Center for Molecular Medicine (F.P.); and Dynamic and Functional in vivo Imaging, Freie Universität (R.A.N.) Berlin, Germany.
Raluca Aura NiesnerFrom the Departments of Rheumatology and Clinical Immunology (R.R., A.E.H., R.U.) and Neuropathology (R.R., H.R.), Charité - Universitätsmedizin Berlin; Deutsches Rheuma-Forschungszentrum, a Leibniz Institute, Immune Dynamics (A.E.H., R.G.) and Biophysical Analytics (A.R., R.A.N.), Berlin; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin (F.P.), Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max-Delbrueck Center for Molecular Medicine (F.P.); and Dynamic and Functional in vivo Imaging, Freie Universität (R.A.N.) Berlin, Germany.ORCID 0000-0001-8969-5432
Anja Erika HauserFrom the Departments of Rheumatology and Clinical Immunology (R.R., A.E.H., R.U.) and Neuropathology (R.R., H.R.), Charité - Universitätsmedizin Berlin; Deutsches Rheuma-Forschungszentrum, a Leibniz Institute, Immune Dynamics (A.E.H., R.G.) and Biophysical Analytics (A.R., R.A.N.), Berlin; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin (F.P.), Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max-Delbrueck Center for Molecular Medicine (F.P.); and Dynamic and Functional in vivo Imaging, Freie Universität (R.A.N.) Berlin, Germany.ORCID 0000-0002-7725-9526

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesInflammatory demyelinating diseases of the CNS, chief among them multiple sclerosis (MS), are a major cause of disability in young adults. Early manifestations of MS commonly involve visual dysfunction, which is often caused by optic neuritis and is accompanied by quantifiable structural changes of the anterior visual pathway. Retinal optical coherence tomography (OCT) has emerged as an important tool for clinical assessment of these structural alterations, but the underlying pathobiological mechanisms and temporal dynamics are yet poorly understood at a cellular level.

methodsUsing the experimental autoimmune encephalomyelitis (EAE) model of MS in fluorescent reporter mouse strains for neuronal function and innate immune cells, we use a unique combination of retinal intravital 2-photon microscopy (2PM) and OCT. In this fashion, we elucidate the spatiotemporal interplay of functional and structural retinal changes over the course of 1 month after EAE induction, with histopathologic imaging validating main results.

resultsWhile all mice display histologic signs of optic neuritis early after EAE induction and independently of motor symptom severity, retinal signs of neuronal stress and parenchymal immune activation spike well after clinical peak of disease, with no signs of lasting structural damage appearing within 1 month after EAE induction. Thus, local retinal endpoints appear to be functions of downstream axonal damage rather than of immediate immune activation directed at the retina. However, as early as 1 week after EAE induction, retinal 2PM can detect recruitment of perivascular immune cells towards the optic nerve (ON), providing the earliest sign of disease activity in otherwise clinically inconspicuous mice. DISCUSSION: Our work identifies the recruitment of CX3CR1+ cells to the ON as an early sign of disease underlining the importance of combined structural and functional retinal imaging for the spatiotemporal characterization of neuroinflammatory and neurodegenerative processes. It further proposes retinal phagocyte orientation, morphology, and abundance as potential surrogate markers for neurodegenerative activity.

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalMice, Inbred C57BLOptic NeuritisRetinaTomography, Optical CoherenceAnimalsFemaleMiceMice, TransgenicMultimodal Imaging

Identifiers

PMID39661921
PMCPMC11637508

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.